登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov 上登记的一项多发性骨髓瘤开放试验。牵头方不是本站收录的医院;本站收录的 3 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 3
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 研究中心首都医科大学附属北京朝阳医院Beijing Chao-Yang Hospital北京医院页面
- 研究中心浙江大学医学院附属第一医院First Affiliated Hospital, Zhejiang University杭州医院页面
- 研究中心北京大学第三医院Peking University Third Hospital北京医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT05565807,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Previously treated with at least three drugs (including PI, IMiD, and anti-CD38 antibody), and relapsed/refractory after the most recent anti-MM therapy.
入选标准第 2 条
Women of childbearing potential (WOCBP) (infertile women are defined as sexually mature females who had undergone a hysterectomy or bilateral oophorectomy or bilateral salpingectomy or bilateral tubal ligation/closure, or who are infertile due to a congenital or acquired condition or spontaneously menopausal for ≥ 12 months) must have a negative blood pregnancy test during the screening. Female subjects of childbearing potential and male subjects with fertility must use a highly effective method of contraception from screening to 6 months after the last treatment.
入选标准第 9 条
Had received plasma exchange therapy within 28 days before the first administration of the study drug.
排除标准第 8 条
Had received the following anti-tumor treatments before the first administration of the study drug: monoclonal antibody or cytotoxic drug or radiotherapy within 28 days; immunoregulator, targeted therapy or epigenetic therapy or investigational medical product or invasive investigational medical device or other anti-myeloma therapy within 28 days or 5 half-lives (whichever is shorter); proteasome inhibitor or anti-tumor traditional Chinese medicine treatment or corticosteroids with a cumulative dose of more than 140 mg prednisone (or equivalent) or a single dose of more than 40 mg/day dexamethasone (or equivalent) within 14 days.
排除标准第 9 条
Had received CAR-T therapy or allogeneic hematopoietic stem cell transplantation therapy within 6 months before the first administration of the study drug, or have a concomitant disease of active graft-versus-host disease (GvHD) at screening.
排除标准第 10 条
Had received autologous hematopoietic stem cell transplantation within 12 weeks before the first administration of the study drug.
排除标准第 11 条
The toxicity caused by the previous anti-tumor treatment did not subside to ≤ grade 1.
排除标准第 16 条
ECOG performance status score is 0, 1, or 2.
入选标准第 7 条
Hemoglobin <80g/L
排除标准第 18 条
Platelet count <50×10\^9/L
排除标准第 19 条
Absolute neutrophil count <1.0×10\^9/L
排除标准第 20 条
Estimated creatinine clearance <30mL/min.
排除标准第 22 条
AST or ALT>3×upper limit of normal (ULN) or serum total bilirubin> 1.5×ULN.
排除标准第 23 条
Diagnosis of MM according to IMWG criteria with measurable lesions, meeting at least 1 of the following criteria:
入选标准第 3 条
Other malignant diseases within 3 years before the first administration of the study drug.
排除标准第 13 条
Is currently pregnant or breast feeding.
排除标准第 39 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义)。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05565807,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Age ≥18 years old, regardless of gender. Previously treated with at least three drugs (including PI, IMiD, and anti-CD38 antibody), and relapsed/refractory after the most recent anti-MM therapy. Diagnosis of MM according to IMWG criteria with measurable lesions, meeting at least 1 of the following criteria: Serum M protein ≥ 0.5g/dL (≥ 5 g/L); or Urine M protein ≥ 200mg/24 hours; or When the serum free light chain (FLC) ratio is abnormal, the affected FLC level is ≥10mg/dL (≥100 mg/L) (the normal FLC ratio is 0.26 to 1.65). ECOG performance status score is 0, 1, or 2. Willing and able to comply with the study schedule and all other study protocol requirements. Women of childbearing potential (WOCBP) (infertile women are defined as sexually mature females who had undergone a hysterectomy or bilateral oophorectomy or bilateral salpingectomy or bilateral tubal ligation/closure, or who are infertile due to a congenital or acquired condition or spontaneously menopausal for ≥ 12 months) must have a negative blood pregnancy test during the screening. Female subjects of childbearing potential and male subjects with fertility must use a highly effective method of contraception from screening to 6 months after the last treatment.排除标准:Exclusion Criteria:
Known hypersensitivity to any of the ingredients of this product. Diagnosis of active plasma cell leukemia. Diagnosis of systemic light chain amyloidosis. MM involving the central nervous system. Has POEMS syndrome. There is spinal cord compression associated with MM. Needs to take concomitant drugs with a strong inhibitory effect or a strong induction effect on CYP3A4. Had received plasma exchange therapy within 28 days before the first administration of the study drug. Had received the following anti-tumor treatments before the first administration of the study drug: monoclonal antibody or cytotoxic drug or radiotherapy within 28 days; immunoregulator, targeted therapy or epigenetic therapy or investigational medical product or invasive investigational medical device or other anti-myeloma therapy within 28 days or 5 half-lives (whichever is shorter); proteasome inhibitor or anti-tumor traditional Chinese medicine treatment or corticosteroids with a cumulative dose of more than 140 mg prednisone (or equivalent) or a single dose of more than 40 mg/day dexamethasone (or equivalent) within 14 days. Had received CAR-T therapy or allogeneic hematopoietic stem cell transplantation therapy within 6 months before the first administration of the study drug, or have a concomitant disease of active graft-versus-host disease (GvHD) at screening. Had received autologous hematopoietic stem cell transplantation within 12 weeks before the first administration of the study drug. Had undergone major surgery or eye surgery within 28 days before the first administration of the study drug. Other malignant diseases within 3 years before the first administration of the study drug. History of grade ≥3 (muscle paralysis, eyelid disease, glaucoma requiring drug control, tearing eyes), or grade ≥2 any other ocular disease (as judged by NCI-CTCAE version 5.0) at screening. Has ≥ Grade 3 neuropathy or Grade 2 neuropathy with associated pain. The toxicity caused by the previous anti-tumor treatment did not subside to ≤ grade 1. Has the following hematological test results within 7 days before the first administration of the study drug: Hemoglobin <80g/L Platelet count <50×10\^9/L Absolute neutrophil count <1.0×10\^9/L Has the following blood chemistry test results within 7 days before the first administration of the study drug: Estimated creatinine clearance <30mL/min. AST or ALT>3×upper limit of normal (ULN) or serum total bilirubin> 1.5×ULN. Severe or uncontrolled cardiovascular and cerebrovascular diseases requiring treatment, including: New York Heart Association class>2; Unstable angina pectoris that cannot be controlled by drugs; Myocardial infarction occurred within 6 months before the first administration of the study drug; Poorly controlled arrhythmias; 12-lead ECG QTcF>470msec; Left ventricular ejection fraction <40%; Poorly controlled hypertension ; Stroke, cerebrovascular accident, or transient ischemic attack occurred within 6 months before the first administration of the study drug. Meets any of the following criteria: Known chronic obstructive pulmonary disease (COPD) and forced expiratory volume in 1 second (FEV1) <50% of predicted normal; Known moderate or severe persistent asthma, or a history of asthma within the past 2 years, or current uncontrolled asthma of any classification; with interstitial lung disease requiring corticosteroid therapy, drug-induced interstitial lung disease, a history of radiation pneumonitis, orclinically active interstitial lung disease suggested by any current evidence before the first administration of the study drug. Has an active bacterial, viral, or fungal infection or needs for intravenous antibiotic administration (IV) within 72 hours before the first administration of the study drug. Active or uncontrolled HBV , HCV , HIV positive. Is currently pregnant or breast feeding. Has any active severe mental illness, medical illness, or other symptoms/conditions that may affect treatment, compliance, or the ability to provide informed consent, as determined by the investigator.
引自 ClinicalTrials.gov, NCT05565807, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05565807,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。